Global Degenerative Disc Disease Treatment Market Size study & Forecast, by Type (Conventional Drugs, Novel Therapies) by End-user (Hospitals, Clinics, Others) and Regional Analysis, 2022-2029

Global Degenerative Disc Disease Treatment Market Size study & Forecast, by Type (Conventional Drugs, Novel Therapies) by End-user (Hospitals, Clinics, Others) and Regional Analysis, 2022-2029

Global Degenerative Disc Disease Treatment Market is valued at approximately USD 26.05 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.4% over the forecast period 2022-2029. Degenerative disc disease (DDD) is a medical condition that results in the degeneration of one or more discs between the vertebrae of the spinal column. In that condition, the injured spinal disc leads patients to have chronic low back discomfort and potentially causes long-term impairment. the treatment involves muscle relaxers, pain relief medications, steroids, and Non-steroidal Anti-inflammatory Drugs (NSAIDs). The growing availability of both non-surgical and spinal fusion process, rising clinical approvals, and increasing healthcare expenditure are some chief factors that are surging the market demand in the global market.

The rising prevalence of chronic lower back pain is bolstering the need for degenerative disc disease therapy among the population, especially among senior people. For instance, the International Association for the Study of Pain published statistics from 2021 that predicted the point prevalence of low back pain (LBP) to be around 7.5% of the world's population. Similarly, a 2021 article from the National Centers for Biotechnology Information (NCBI) reported that the prevalence of disc degeneration was 12.4% in the population between the ages of 18 and 29 and soared to 98.2% in those between the ages of 60 and 69. Therefore, these aforementioned factors are stipulating the market growth across the globe. Moreover, the rising launch of innovative and technologically advanced products, as well as the growing R&D investments are presenting various lucrative opportunities over the forecasting years. However, limited availability of effective drugs and novel therapies for the treatment of this condition and presence of alternative therapies are challenging the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Degenerative Disc Disease Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing adoption of drugs and treatments among the patient population, along with the rising prevalence of the condition, Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the surging demand for the drugs for various treatment, escalating target population, as well as increasing diagnosis of the condition in the market space.

Major market players included in this report are:
B. Braun Melsungen AG
Pfizer Inc.
Novartis AG
Eli Lilly and Company
DiscGenics, Inc.
Spine BioPharma
FibroGenesis
Ferring B.V.
Globus Medical
Paradigm Spine LLC

Recent Developments in the Market:
 In March 2022, Pfizer Inc. announced the acquisition of Arena- a clinical-stage company developing innovative potential therapies to cure immuno-inflammatory diseases. The primary objective of this initiative is the strengthening of the product portfolio.
 In December 2021, Teva Pharmaceutical Industries Ltd. declared the introduction of Ibuprofen 800 mg tablets, the generic version of Duexis, indicated for pain management in the U.S., which aims to boost the company’s product portfolio.

Global Degenerative Disc Disease Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Conventional Drugs
Novel Therapies
By End-user:
Hospitals
Clinics
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

B. Braun Melsungen AG
Pfizer Inc.
Novartis AG
Eli Lilly and Company
DiscGenics, Inc.
Spine BioPharma
FibroGenesis
Ferring B.V.
Globus Medical
Paradigm Spine LLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.